All the Drug Class Drugs
Antivirals. Podophyllotoxin 5 mg/ml. SOL.: 3.5 ml (with cotton applic. tips).
Apply twice dly. for 3 consec. days.
Then a tmt. free interval of 4 d. Ther.
can be repeated up to max. duration of
4 wks. Lesions in female & lesions
greater than 4cm2 in male should be
treat. under direct med. supervis.
Otherwise tmt. at home.
Ext. genital warts.
C/I: Hypersens., Pregn, lact., child. under
12 yrs. old. Inflamed or bleed. pointed
condylomata, or open wounds follow.
surgical procedures. Simultan. admin. of
other preparat. contain. Podophylline.
Antivirals. Sofosbuvir 400 mg, Velpatasvir 100 mg. F.C. TABS.: 28. One tab., taken oral., once dly. with or without food. See lit.
Treatment of chronic hepatitis C virus
(HCV) infection in adults.
C/I: Hypersens.
Meds. that are strong P-gp and/or strong P450 CYP induc.(carbamazepine, phenobarbital, phenytoin, rifampicin, rifabutin and St. John’s wort).
Antivirals, Protease Inhibitors. nirmatrelvir 150 mg, Ritonavir 100 mg. 20 X FC pink tabs contain.150 mg of nirmatrelvir.
10 XFC white to off white tabs contain.100 mg of ritonavir.
Recomm. dosage is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) all taken together orally every 12 hours for 5 days. This drug should be admin. as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset.
Tmt. of confirmed coronavirus dis. 2019 (COVID-19) in adults
who do not require suppl. oxygen and who are at incr. risk for progressing to sev. COVID-19
C/I: Hypersens.
Medic. prod. listed below are a guide and not considered a comprehensive list of all possible medic. prod. that are contraind. with this drug.
Medic. prod. that are highly dependent on CYP3A for clearance and for which elevated plasma concentr. are associated with serious and/or life-threatening reactions.
Alpha1-adrenoreceptor antagonist: alfuzosin
Antianginal: ranolazine
Antiarrhythmic: dronedarone, propafenone, quinidine
Anticancer drugs: neratinib, venetoclax
Anti-gout: colchicine
Antihistamines: terfenadine
Antipsychotics/neuroleptics: lurasidone, pimozide, quetiapine
Benign prostatic hyperplasia medicinal products: silodosin
Cardiovascular medicinal products: eplerenone, ivabradine
Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine
GI motility agents: cisapride
Immunosuppressants: voclosporin
Lipid-modifying agents:
o HMG Co-A reductase inhibitors: lovastatin, simvastatin
o Microsomal triglyceride transfer protein (MTTP) inhibitor: lomitapide
Migraine medicinal products: eletriptan
Mineralocorticoid receptor antagonists: finerenone
Neuropsychiatric agents: cariprazine
Opioid antagonists: naloxegol
PDE5 inhibitor: avanafil, sildenafil, tadalafil, vardenafil
Sedative/hypnotics: clorazepate, diazepam, estazolam, flurazepam, oral midazolam and triazolam
Vasopressin receptor antagonists: tolvaptan
Medic. prod. that are potent CYP3A inducers where significant. reduced nirmatrelvir/ritonavir plasma concentr. may be associated with the potential for loss of virologic response and possible resistance.
Antibiotics: rifampicin, rifapentine
Anticancer drugs: apalutamide, enzalutamide
Anticonvulsants: carbamazepine, phenobarbital, phenytoin, primidone
Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor
Herbal products: St. John's wort (Hypericum perforatum)
This drug cannot be started immediately after discontinuation of CYP3A4 inducers due to the delayed offset of the recently discontinued CYP3A4 inducer.
Antivirals. Elbasvir 50 mg, Grazoprevir 100 mg. F.C. TABS.: 28. The recomm. dosage is 1 tab×1/d taken orally with/without food. For tmt. regimen and duration of ther. See lit.
Tmt. of chron. hepatitis C (CHC) genotypes 1 or 4 infec. in adults.
C/I: Pts. with known hypersens. to elbasvir, grazoprevir.
Pts. with moder. or sev. hep. impair. (ChildPugh B or C).
Concomit. use with inhibit. of organic anion transporting polypeptides 1B1/3 (OATP1B1/3).
Concomit. use with ribavirin.
